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Abstract
The serine/threonine phosphatase calcineurin acts as a crucial connection between calcium signaling the
phosphorylation states of numerous important substrates. These substrates include, but are not limited to,
transcription factors, receptors and channels, proteins associated with mitochondria, and proteins associated with
microtubules. Calcineurin is activated by increases in intracellular calcium concentrations, a process that requires the
calcium sensing protein calmodulin binding to an intrinsically disordered regulatory domain in the phosphatase.
Despite having been studied for around four decades, the activation of calcineurin is not fully understood. This
review largely focuses on what is known about the activation process and highlights aspects that are currently not
understood.
Keywords: Calcineurin, Calmodulin, Calcium, Intrinsically-disordered region, Transcription, Receptors, Channels,
Mitochondria, Microtubules

Background
The serine/threonine phosphatase calcineurin (CaN) is
activated by increased intracellular calcium concentrations [1–4]. Along with the calmodulin-activated kinases
[5], CaN directly links calcium signaling to protein phosphorylation states and plays an essential role in numerous signaling processes [6]. CaN is found in eukaryotes
and is conserved from single cell organisms through to
Homo sapiens [2, 7]. Although this review deals primarily with the human isoforms, much of what is covered
should be applicable to other organisms.
This review will largely focus on how calcium acts to
activate CaN but will start with a brief introduction to
how CaN is coupled to calcium signaling, and to some
of the phosphatase’s substrates and the signaling processes of which they are a part (summarized in Table 1).
This should not be taken as an exhaustive list of substrates nor a definitive description of how CaN modulates their activities. Indeed, how CaN recognizes its
substrates is an active area of study, and there are
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ongoing efforts to identify and characterize more CaN
substrates [32, 33].

Signaling
Calcium signaling, calcineurin, and calmodulin

CaN is activated in response to increases in calcium concentrations in the cell [1, 2, 34]. The molecular details of
the activation process will be discussed in detail below,
but in short both CaN and the calcium-sensing protein
calmodulin (CaM) bind calcium, with CaM then binding
to CaN. The CaM:CaN complex forms the active phosphatase. This process directly couples calcium signaling
to dephosphorylation in much the same way that calcium signaling is coupled to phosphorylation through
the CaM-modulated kinases [5]. One notable difference
however is that there are multiple CaM-modulated kinases but CaN is the only phosphatase known to be directly activated by calcium.
A brief discussion of CaM is warranted. This calciumsensing protein plays critical roles in numerous processes and is known to have in excess of 200 different
substrates [35, 36]. These encompass a broad range of
proteins and enzymes. These include, but are not limited
to, the previously-mentioned the CaM-modulated
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Table 1 Signaling processes that calcineurin plays roles in and example substrates
Signaling processes/molecules

Example calcineurin substrates

Transcription

NFATs (nuclear factors of activated T-cells) [3, 4, 8–16]
FOXO (forkhead transcription factors) [17, 18]
MEF2 (myocyte-specific enhancer factor 2) [13, 15, 16]
TFEB (transcription factor EB) [12, 16, 18, 19]

Receptors and channels

AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors) [20, 21]
NMDARs (NMDA-type ionotropic glutamate receptors) [20, 21]
TRESK (tandem-pore-domain weakly inward rectifying potassium channels (TWIK)-related
spinal cord potassium channels) [22–24]
NHE1 (Na+/H+ exchanger 1) [16, 25, 26]

Mitochondria

DRP1 (dynamin-related protein 1) [27]
BAD (Bcl-2/Bcl-XL-antagonist, causing cell death) [28–30]

Microtubules

tau [31]
MAP2 [31]

kinases [5], nitric oxide synthases [37], the calciumrelease channel ryanodine receptors [38], proteins such
as neurogranin and growth-associated protein-43 [39],
and even the microtubule-associated protein tau [40,
41]. Notably, CaM modulates the activities of enzymes
such as CaN and the CaM-modulated kinases which are
involved in numerous signaling processes.
Interestingly it has been suggested by Persechini and
Stemmer that CaM concentrations in cells are limiting
[42]. In other words, there are more potential substrate
molecules than CaM molecules available to bind to
them. The concentration of CaM in mammalian cells
has been estimated to be around 5 μM [43]. As noted by
Persechini and Stemmer, this concentration is comparable to both the high end of calcium concentrations and
the concentrations of some substrates [42]. As noted by
these authors, CaM activity will thus be regulated by its
proximity to substrate and released calcium, plus substrate affinity.
CaN is primarily located in the cytosol [2]. A-kinase anchoring protein-79 is known to bind inactive CaN and
localize it to the plasma membrane in the vicinity of calcium channels [44–46]. This would put CaN in a favorable
location for binding CaM upon increases in intracellular
calcium concentration. Furthermore, CaM’s affinity for
CaN is in the low picomolar range, making this the tightest known CaM:substrate binding [47–49]. Taken together, these observations suggest that CaN is a
particularly important CaM substrate and that downstream targets of CaN are also of some importance. Some
of these downstream targets will now be discussed.
Transcription factors

The most studied substrates of CaN are the family of
nuclear factors of activated T-cells (NFATs) [3, 4, 8].
The desphosphorylation of an NFAT in the cytosol results in exposure of a cryptic nuclear localization signal,
resulting in the NFAT moving into the nucleus and activating a variety of transcription programs. Perhaps the

most well-known of these are processes that result in activation of T cells within the immune system [9, 10]. For
this reason, the immunosuppressant drugs tacrolimus
and cyclosporin are used to bind to and inhibit CaN
[33]. The NFATs dephosphorylated by CaN activate
transcription programs in other systems such as neurons
and astrocytes [11, 12], as well as the heart and skeletal
muscle [13–16].
Other transcription factors are regulated by dephosphorylation by CaN. CaN dephosphorylates the forkhead transcription factors (FOXO) involved in
metabolism and autophagy [17, 18]. Other transcription factor substrates include the myocyte-specific enhancer factor 2 (MEF2) [13, 15, 16] and transcription
factor EB (TFEB) [12, 16, 18, 19]. The latter two transcription factors regulate a wide variety of processes
including cardiac function, neuronal function, and
autophagy.
Receptors and channels

CaN is also known to interact with and help regulate the
activity of several receptors and ion channels. These in
turn control a variety of signaling pathways. CaN dephosphorylates the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and the NMDA-type
ionotropic glutamate receptors (NMDARs), playing crucial roles in synaptic long term potentiation and long term
depression [20, 21]. It is also involved in modulating the
activity of tandem-pore-domain weakly inward rectifying
potassium channels (TWIK)-related spinal cord potassium
(TRESK) channels in the central nervous system as well as
in immunological response [22–24]. CaN has also been
identified as an important regulator of the Na+/H+ exchanger 1 (NHE1) [16, 25, 26].
Mitochondria associated proteins

CaN has been linked with a number of proteins associated with mitochondria for quite some time [27, 28, 50].
For example, CaN dephosphorylates dynamin-related
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protein 1 (DRP1), linking catecholamines, via calcium
signaling, to mitochondrial fission [27]. In addition,
apoptosis initiated by sustained increases in intracellular
calcium concentrations occurs via CaN dephosphorylation of the protein BAD (Bcl-2/Bcl-XL-antagonist, causing cell death) [28–30].

Microtubule-associated proteins

Calcium signaling is linked to neuronal cytoskeletal
dynamics, and neurodegeneration, in part through
CaN [31]. CaN is one of the phosphatases known to
dephosphorylate the microtubule-associated proteins
tau and MAP2. The phosphorylation state of these
proteins controls their binding to and stabilization of
microtubules. The phosphorylation state of tau also
controls its association with stress granules within
neurons [51].
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Structure and function
CaN structure

Calcineurin (CaN) is a heterodimer expressed as three
different isoforms; αCaN, βCaN and γCaN [1–3]. The
overall domain and three-dimensional structure of each
isoform is much the same with a catalytic A chain
(CnA) and calcium-binding regulatory B chain. The ~
58–64 kDa A consists of the catalytic domain, a B chainbinding helix, the regulatory domain, an autoinhibitory
domain, and an unstructured C-terminal domain of unknown function (Fig. 1a). The ~ 19 kDa B chain (CnB) is
structurally homologous to calmodulin (CaM) and consists of two calcium-binding lobes connected by a short
linker. Each lobe of CnB consists of two calcium-binding
EF hands [1, 52–54].
The crystal structure of the calcium-loaded human
αCaN (PDB ID 1AUI [55];) is shown in Fig. 1b. Notably,
the 96-residue regulatory domain and 35-residue C-

Fig. 1 a. Domain structures of the CaN A chains from the three human isoforms. The residue numbering for αCaN was taken from the crystal
structure (PDBID 1AUI [55];). For the β and γ isoforms, the regions of greatest difference with the α isoform are highlighted. b. Crystal structure of
human αCaN (PDBID 1AUI [55];). The A chain is colored blue and the B chain green. The orange and yellow spheres denote a Zn-Fe center in the
active site in the catalytic domain and the grey spheres denote Ca2+ bound to the B chain. Residues within the A chain between and beyond
which electron density is not detected are indicated. The green oval denotes the location of the PxIxIT substrate binding site and the blue oval
the LxVP substrate binding site
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terminal domain are not seen in the structure due to a
lack of electron density. This suggests that these domains occupy multiple conformations in the crystal.
Multiple structures of intact CaN, all in the calciumbound state, have been deposited in the PDB with the
regulatory and C-terminal domains remaining unseen in
all [26, 56–60].
Depictions of the domain composition of each of the
three isoforms of CaN are given in Fig. 1a. The α isoform of CaN was the first identified, is the simplest, and
is the dominant form in neurons [1–3]. It consists of the
αCnA and CnB1 chains. The β isoform is the dominant
form in most non-neuronal cell types and consists of
βCnA and CnB1 chains. The major difference between
βCnA and αCnA is an N-terminal proline-rich extension, including a run of ten consecutive prolines, on the
former isoform. Little is known about this extension although there is some evidence that it is involved in
modulating substrate specificity [61]. The γ isoform consists of γCnA and CnB2 chains. This isoform was
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initially thought to be testes specific but has more recently been found to be more broadly distributed, albeit
at low levels, and has been implicated as playing a role
in schizophrenia [62–64]. γCnA differs from αCnA
largely by a basic residue-rich region at the end of the
C-terminal domain [1–3]. The function of this region is
currently unknown. The human CnB1 and CnB2 isoforms differ by just three residues in length, have 83%
sequence identity, and appear to function identically.
Disorder within CaN

As noted above, the 96-residue regulatory and 35residue C-terminal domains of the αCnA chain are not
observed in crystal structures of CaN (see Fig. 1b). There
are an additional thirteen residues at the N-terminus of
this chain that are also not observed, along with four
residues of the N-terminus of the CnB1 chain. Predictions from the PONDR VLXT disorder predictor [65,
66] for the human αCnA and CnB1 chains are shown in
Fig. 2. Regions with scores above 0.5 are predicted to be

Fig. 2 Disorder predictions for the human αCnA (top panel) and CnB1 (bottom panel) chains. Values above 0.5 denote predicted disorder. Major
regions of predicted disordered are marked with red bars
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disordered. Major regions of predicted disorder are denoted with red bars in Fig. 2. Interestingly there is a region between residues 34 and 76 in αCnA that is
predicted to be disordered but is clearly a well-ordered
segment of the catalytic domain in known CaN crystal
structures. Aside from that region, two others in αCnA
are strongly predicted to be disordered. These are the
regulatory and C-terminal domains. The short region of
predicted order between these two disordered regions
corresponds to the start of the autoinhibitory domain.
A significant portion of the N-terminal lobe of CnB1
is predicted to be disordered (Fig. 2), and yet is clearly
well-folded in the crystal structure (Fig. 1b). As is discussed below this lobe of CnB1 is thought to be dynamic
in the activation process.
It is not clear what role the 35-residue C-terminal tail
of the αCnA chain might play. As will be discussed
below, the regulatory domain is an important component in the activation of CaN, with the disorder within
that domain playing an essential role.
Substrate binding

Substrates do not appear to bind directly in the CaN active site cleft. Rather, there are two substrate binding sites
on the surface of the phosphatase. These are named the
PxIxIT and LxVP sites based on the consensus binding
motifs [4, 32, 33, 58, 67–70]. Many known CaN substrates
possess both motifs with the sites to be dephosphorylated
generally located between the two, although there are
some substrates with just one binding motif [45]. The
PxIxIT site is located on the side of the catalytic domain
and is always accessible (green oval in Fig. 1b) [58, 59, 71,
72]. Sequences that bind to this site bind directly to an
edge strand of a β-sheet, acting as an additional strand.
The second binding site, LxVP, is located at the interface of the B chain binding helix in the A chain and the
C-terminal lobe of the B chain (blue oval in Fig. 1b) [4,
58, 69, 71, 73]. The well-known immunosuppressant
drugs cyclosporin and tacrolimus (FK506) bind in this
region and inhibit substrate binding [55, 74, 75]. LxVP is
actually something of a misnomer for the binding motif.
It has been shown that a polar/aromatic residue pair are
favored immediately before the leucine, leading to the
suggestion that the motif should more accurately be
called πϕLxVP [60]. Notably, the LxVP binding site is
only accessible when CaN is fully active.
Activation

It has been known for some time that CaN is activated
in response to increased intracellular calcium concentrations and that full activation requires the calciumsensing protein calmodulin (CaM) [1–3, 34]. A detailed
description of the full activation process is not available,
but it does appear to involve three distinct states (Fig. 3).
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What is known has been determined largely through
study of the αCaN isoform, but there are no compelling
reasons to believe the activation processes of the βCaN
and γCaN isoforms differ significantly.
Inactive CaN

The inactive state of CaN (Fig. 3a) exists at basal intracellular calcium levels which have been estimated to be
around 100 nM [76]. Much of what we know about the
inactive state was determined by the groups of Klee [52,
53, 77–79] and Perrino [80, 81]. Klee and co-workers
demonstrated that both the regulatory domain of the
αCnA chain and the linker between the two lobes of the
CnB1 chain were susceptible to cleavage in limited proteolysis experiments in calcium-dependent manners [52,
77, 78]. In the absence of calcium, or at low concentrations, the regulatory domain is protected from proteolysis, whereas at high calcium concentrations, but in the
absence of CaM, it is readily cleaved into multiple small
fragments. This observation suggests that the regulatory
domain is folded at basal calcium levels and becomes
unfolded, or disordered, when calcium concentrations
increase. In contrast, at low calcium concentrations the
linker connecting the two calcium-binding lobes of
CnB1 is cleaved in limited proteolysis but becomes protected at higher concentrations. Furthermore, when
CnB1 is cleaved at low calcium concentrations the Nterminal lobe of the chain is released while the Cterminal lobe remains tightly bound to the αCnA chain.
Little is known about the calcium-binding properties
of CnB1. Gallagher et al. determined the calcium affinities for the isolated CnB1 chain and found the two sites
in the N-terminal lobe had affinities in the 11–81 μM
range and the two in the C-terminal lobe in the 30–150
nM range [82]. These affinities would support the idea
that the N-terminal lobe does not have calcium bound
at basal intracellular concentrations but that the Cterminal lobe might have one or even two calcium ions
bound. It’s important to note however that these affinities will be altered when CnB1 is bound to the αCnA
chain.
Perrino et al. [81] generated αCnA chain constructs
where the chain was truncated either just before the
CaM binding site within the regulatory domain or just
after the CaM binding site and combined these with
CnB1. The former truncation resulted in an αCaN that
was largely active against a substrate that bound to the
LxVP binding site regardless of the calcium concentration. The latter truncated αCaN however required both
elevated calcium and the presence of CaM to be fully active. This suggests that the CaM binding site within the
regulatory domain contains elements that inhibit substrate binding to the LxVP site at the interface formed
by the B chain binding helix in the A chain and the C-
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Fig. 3 Proposed models for the (a) inactive, (b) partially active, and c. fully active states of CaN. The inactive state (a) occurs at basal calcium
concentrations and is thought to have the regulatory domain folded onto the B chain binding helix and the N-terminal lobe of CnB1 unbound.
The partially active state (b) occurs when calcium is bound to CnB1 but prior to CaM binding. In this state the N-terminal lobe of CnB1 binds to
the B chain binding helix, releasing the regulatory domain into a disordered state. The fully active state (c) occurs when holo-CaM has bound to
CaN causing the regulatory domain to fold and removing the autoinhbitory domain from the active site

terminal lobe of CnB1. Others have since published evidence that the regulatory domain contains autoinhibitory elements that function in conjunction with the
autoinhibitory domain to keep CaN inactive at low calcium concentrations [57, 80, 83, 84].
Taken together the above observations lead to a model
for the inactive state of αCaN where the N-terminal lobe
of CnB1 is not bound to the B chain binding helix of the
αCnA chain, likely due to that lobe being devoid of calcium (Fig. 3a) [1, 34, 82]. This allows the regulatory domain to be folded onto the B chain binding helix and
the interface between that helix and the C-terminal lobe
of CnB1. Under these conditions the autoinhibitory domain would be bound to the active site cleft of the catalytic domain keeping the phosphatase inactive (Fig. 3a).
Partially active CaN

A partially active state of αCaN is obtained when calcium concentrations are increased but CaM is not
present [52, 53, 79, 85]. All published crystal structures
of full-length human CaN are of this calcium-loaded
form (e.g. 1AUI [55] as shown in Fig. 1b). Each lobe of
CnB1 has two calcium ions bound, and the N-terminal
lobe is bound to the B chain binding helix in the A

chain. The regulatory domain of the A chain is not seen in
these structures and has been shown to be readily cleaved
in limited proteolysis experiments [52, 77, 78]. Of note, in
those proteolysis experiments CnB1 was not susceptible
to cleavage when fully calcium loaded. Although the autoinhibitory domain is bound in the active site cleft in the
crystal structures of the calcium-loaded form of CaN,
in vitro experiments have demonstrated that this form is
somewhat active [52, 53, 79, 85]. This suggests that the
autoinhibitory domain is not tightly bound in this state.
The lack of electron density for the 96-residue regulatory domain in CaN crystal structures, and its vulnerability to proteolysis, spurred Dunker and co-workers to
consider that this domain might be devoid of structure
and to subsequently develop predictors of protein disorder [65, 86]. Creamer and co-workers have used a variety of techniques to probe the conformational
properties of the regulatory domain in calcium-loaded
human αCaN [34, 87–91]. A combination of circular dichroism (CD) spectrapolarimetry, fluorescence spectroscopy, hydrogen-deuterium exchange mass spectrometry
(HXMS), and limited tryptic digestion was used to demonstrate that the regulatory domain was indeed intrinsically disordered in the partially active form of αCaN [87,
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88]. Later, in collaboration with the Fitzkee laboratory,
NMR was employed to confirm these findings [91].
In Fourier transform infrared spectroscopy (FTIR) experiments, Fu et al. [92] found the regulatory domain of
CaN to exist in a very dynamic state supporting the idea
that it is intrinsically disordered.
The above observations suggest the model for partially
active CaN illustrated in Fig. 3b. The increased calcium
concentration leads to both lobes of CnB1 becoming
fully loaded with the metal ion. The N-terminal lobe of
CnB1 binds to the B chain binding helix, causing the
regulatory domain to unfold and become disordered.
The disordered regulatory domain at least partially exposes the previously occluded LxVP site, allowing substrate to bind. The unfolding of the regulatory domain
also presumably weakens the binding of the autoinhibitory domain in the active site cleft of the catalytic domain allowing for partial activity.
Fully active CaN

Full activation of CaN requires both calcium and
calcium-loaded CaM (holo-CaM) to bind to the phosphatase [1–3]. It has been known for some time that
holo-CaM binds to a 24-residue region within the regulatory domain of the A chain (the CaM binding region;
Fig. 4a) and that binding results in release of the
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autoinhibitory domain from the active site cleft. It has
also been known for almost four decades that the regulatory domain in this fully active state is conformationally
distinct from that in the partially active state. This was
determined by Klee and co-workers in their limited proteolysis experiments [52, 77, 78]. These workers found
that the regulatory domain, which is readily cleaved in
partially active CaN, is protected from proteolysis when
holo-CaM is bound in the fully active state.
There was some controversy over how CaM bound to
its CaM binding region in CaN. Jia and co-workers published crystal structures of holo-CaM bound to the CaN
CaM binding region that had two CaM molecules sharing binding to two CaN CaM binding region peptides
(Fig. 4b) [93, 94]. Majava and Kursula solved a similar
crystal structure, but went on the perform extensive
hydrodynamic experiments including small-angle X-ray
scattering and size-exclusion chromatography that indicated the stoichiometry of the CaM:CaM binding region
peptide complex was 1:1 in solution [95]. In their first
paper on the 2:2 structure, Ye et al. also presented gel
filtration data suggesting the complex predominantly
was 1:1 in solution [93]. O’Donnell et al. used multiple
hydrodynamic measurements to determine that holoCaM bound to the CaM binding region from βCaN with
a 1:1 stoichiometry [48]. In later work, Jia and co-

Fig. 4 a. Sequence of the regulatory domain (regulatory domain) from the human αCaN A chain with the CaM binding region denoted by the
green box. b. 2:2 stoichiometric structure of holo-CaM bound to the CaM binding region from αCaN (PDBID 2R28 [93, 94];). Holo-CaM is colored
green, the CaM binding region blue, and the grey spheres are Ca2+. C. 1:1 stoichiometric structure of holo-CaM bound to the CaM binding
region from αCaN (PDBID 4Q5U [89];)
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workers performed small-angle X-ray scattering on
holo-CaM bound to the regulatory domain from αCaN
and found they could only fit a 1:1 complex to the
resulting envelop [56]. Dunlap et al. solved the crystal
structure of holo-CaM bound to the CaM binding region
from αCaN and obtained a 1:1 complex (Fig. 4c) [89].
These authors used size-exclusion chromatography and
rotational correlation coefficients determined using
time-resolved fluorescence spectroscopy to show the
holo-CaM:CaM binding region complex had an almost
entirely 1:1 stoichiometry in solution. The overwhelming
majority of the evidence thus points to a single holoCaM binding to a single CaN CaM binding region.
Creamer and co-workers have noted that holo-CaM
binding to its known 24-residue binding region within
the regulatory domain would not alone be sufficient to
protect the 96-residue domain from proteolysis [34, 87–
90]. There are, for example, multiple trypsin cleavage
sites (basic residues) within the regulatory domain but
outside the CaM binding site (Fig. 4a). The CaM binding
region folding into an α-helix is also unlikely to be sufficient to remove the autoinhibitory domain from the active site cleft given there are around 55 residues between
the end of the CaM binding region and the start of the
autoinhibitory domain.
A HXMS experiment involving holo-CaM binding to
an isolated regulatory domain construct indicated that a
~ 35-residue region of the regulatory domain C-terminal
to the CaM binding region was somewhat protected
from exchange suggesting that this region became structured upon binding [87]. Careful analysis of CD spectra
led to the suggestion that a second, distal helical region
formed in the regulatory domain upon holo-CaM binding and that this distal helix was folded onto the surface
of CaM. In their work on holo-CaM bound to the regulatory domain Jia and co-workers found they could fit an
additional α-helix in the envelop obtained from smallangle X-ray scattering measurements [56].
By plotting the sequence on a helical wheel Dunlap
et al. were able to determine the most likely region for
this distal helix was residues 441 to 458 [88]. This
stretch of sequence could potentially form an amphipathic helix. In order to test this, each of the three alanines on the putative hydrophobic face were individually
mutated to glutamate. Each of these mutations reduced
the helical content of the holo-CaM-bound regulatory
domain but did not abolish binding. Furthermore, these
mutations greatly reduced the activity of holo-CaMbound full-length αCaN indicating that formation of the
distal helix is crucial for full activation of the phosphatase [88].
The holo-CaM:regulatory domain complex has so far
eluded extensive crystallization efforts by the Creamer
laboratory. Yadav et al. used a 15N,13C-labeled construct
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to obtain NMR resonance assignments for the intrinsically disordered regulatory domain [91]. However it was
found that the holo-CaM:regulatory domain complex
was in the slow to intermediate exchange regime, precluding solution of a high resolution structure via NMR.
It is possible that the distal helix region is very dynamic,
making short-lived contacts with the surface of holoCaM but maintaining sufficient structure to exhibit
some protection in HXMS and helical CD signal as observed by Creamer and co-workers [87, 88].
In more recent work, Sun et al. employed a variety of
computational approaches in an attempt to identify
where the distal helix forms on the surface of holo-CaM
[96]. Four putative regions of interaction were identified.
The prediction from these computations was that a helix
encompassing residues 30 through 40 in the N-terminal
lobe of holo-CaM is the most likely site of interaction
with the distal helix. This prediction has yet to be tested
experimentally.
Based on the existing data, the current model for the
fully active state of CaN has holo-CaM bound to the
CaM binding region in the regulatory domain (Fig. 3c).
A region of the regulatory domain C-terminal to the
CaM binding region folds into an α-helix somewhere on
the surface of holo-CaM. The resulting compaction of
the 96-residue regulatory domain is sufficient to dislodge
the autoinhibitory domain from the active site cleft of
CaN leading to its full activation.
Distal helix stability

In their work on the distal helix in the regulatory domain of αCaN, Creamer and co-workers made the somewhat puzzling observation that this helix had a melting
temperature (Tm) of just ~ 38 °C in dilute buffer [90].
The distal helix would be, on average, unfolded and
holo-CaM-bound αCaN presumably not be fully active
nearly half of the time under such circumstances. Of
course, conditions inside a cell are very different to the
dilute solutions employed in the laboratory. Cook and
Creamer were able to show that the Tm of the distal
helix increased to ~ 43 °C in solutions containing 200 g/
L dextran 70 or ficoll 70, conditions that mimic the
crowded interior of cells [90]. Furthermore, the activity
of αCaN was increased in the presence of these crowding agents but not in the presence of an equivalent concentration of sucrose. These observations suggest that
crowding agents increase the stability of distal helix and
that holo-CaM-bound αCaN would be fully active in
cells at normal physiological temperature.
The observed Tm of ~ 43 °C for the distal helix under
cell-like conditions indicates it is just barely stable and
that αCaN activity would be sensitive to relatively small
increases in temperature [90]. This led to the speculation
that perhaps this temperature sensitivity may have
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evolved as a mechanism for controlling fever response.
CaN is known to be involved in the control of inflammation and perhaps fever [97–99]. It has been shown that
expression of Rcan1 (regulator of calcineurin 1), an endogenous inhibitor of CaN, reduces expression of proinflammatory genes [100]. Temperatures associated with
high fever could elicit a similar response by destabilizing
the distal helix thereby allowing the autoinhibitory domain to occupy the active site cleft of CaN.
It is also possible the marginal stability of the distal
helix is an indicator of a dynamic nature as suggested in
the previous section. Beyond the speculated control of
fever and inflammation, the evolutionary advantage of a
dynamic distal helix region is not clear.
Holo-CaM:CaN binding affinity

Hubbard and Klee initially determined that holo-CaM
bound to αCaN with a KD of ~ 16 nM making this one
of the tightest CaM:substrate interactions [101]. Quintana et al. later used stopped-flow fluorescence measurements to study the binding of holo-CaM to αCaN [47].
They measured a significantly tighter KD of ~ 26 pM,
affirming this interaction as the strongest currently
known for a CaM:substrate binding. Following this,
O’Donnell et al. used a variety of biophysical approaches
to probe the binding of holo-CaM to the CaM binding
region from βCaN and estimated a similar very tight KD
of ~1pM [48]. The affinity of holo-CaM for CaN appears
to be the result of very rapid association (4.6 × 107 M− 1
s− 1) and very slow dissociation (0.0012 s− 1) in the presence of saturating calcium concentrations.
Cook and Creamer employed stopped-flow fluorescence to explore the basis for the rapid binding of holoCaM to αCaN [49]. In this work the binding of CaM to
a peptide corresponding to the CaM binding region
(pCaN), a construct consisting of just the regulatory domain, and full-length αCaN was studied. These authors
found that at 37 °C the binding affinity is almost entirely
due to direct interactions between the CaM binding region and holo-CaM, and that the association rate was
sensitive to salt concentration, becoming faster at lower
salt concentrations. This latter observation suggested
that the association was in part driven by electrostatic
interactions, not surprising given holo-CaM is very
acidic and the CaM binding region in αCaN basic. What
was noteworthy was the distribution of charged groups
within the disordered regulatory domain, but outside the
CaM binding region, appeared to play a role in determining the rate of association [49]. Computer simulations of the regulatory domain suggested that the
distribution of charges resulted in the N-terminal half of
the regulatory domain, which contains the CaM binding
region, is more extended than the C-terminal half. This
would result in the CaM binding region being accessible
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to holo-CaM while potentially minimizing unproductive
interactions with the C-terminal half of the regulatory
domain.
Overall it appears that CaN has evolved to bind rapidly
and very tightly to holo-CaM. Indeed this appears to be
the tightest CaM:substrate interaction reported to date.

A conundrum

The studies described above of the binding of holo-CaM
to αCaN have revealed an interesting conundrum: why
has the regulatory domain of CaN evolved to bind very
rapidly and tightly to holo-CaM and also to have a
functionally-important distal helix that is not very stable,
potentially dynamic, at physiologic temperature? It is of
course impossible to know the answer to this, but it is
possible to make some educated speculations.
The very tight binding of holo-CaM to αCaN may be
an indication of the physiologic importance of the phosphatase. It has been suggested that CaM levels in human
cells are limiting [42]. In other words, there are fewer
CaM molecules than there are substrate molecules. The
tight binding of holo-CaM to αCaN would ensure the
phosphatase takes precedent, becoming activated even in
the presence of other CaM substrates. The rapid association could also allow for rapid coupling of increased
calcium levels to phosphorylation states, likely ensuring
that binding of CaM to αCaN is not a rate-limiting step
in associated signaling processes. If this speculation is
correct, then the overall activity of CaN should not be
significantly affected by pathogenic mutations recently
identified in CaM since these occur in just one of three
identical genes that code for the protein [102–106].
Whether that holds true has yet to be seen.
A second potential reason for the very rapid association between CaM and CaN was discussed in an earlier
review on activation of the phosphatase [34]. In that review it was suggested that the regulatory domain was in
fact only transiently disordered. In short, the regulatory
domain is thought to be folded in the inactive state of
CaN (Fig. 3). When intracellular calcium levels rise CnB
binds the metal ion allowing its N-terminal lobe to bind
to the B-chain binding helix of αCnA and releasing the
regulatory domain into a disordered state. Meanwhile,
CaM has also bound calcium and can rapidly bind to the
newly disordered regulatory domain resulting in the later
domain folding into a different conformation and activating the phosphatase. The regulatory domain is thus
disordered for just a short period of time. The disorder
is important in that it could facilitate the rapid binding
of CaM by making the binding site more accessible and
leading to rapid activation [34]. Rapid activation of CaN
would be important in some of its signaling roles. For
example, channels are often open and close quickly (e.g.
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AMPARs [107]), requiring enzymes such as CaN that
modulate their activity to function rapidly.
As suggested previously, the weakly stable, potentially
dynamic, distal helix may have evolved to allow for fine
control of CaN activity in response to increased body
temperature (e.g. due to fever) [90]. This would allow
signaling processes such as those associated with inflammation to be attenuated in response to fever. Unfortunately, this hypothesis would be difficult to test. For
example, raising the temperature of cultured human
cells will result in numerous intracellular responses
complicating efforts to isolate the affects upon CaN
alone.

Conclusions
This enzyme is clearly a vital component of multiple signaling pathways and yet there is still much to learn
about CaN. Our knowledge of the activation process has
gaps including the structures of the inactive state and
the holo-CaM:CaN complex. The evolutionary reasons
for holo-CaM’s affinity for CaN being so high and yet
the functionally vital distal helix formed upon binding
being just marginally stable are matters for speculation.
Furthermore, it is not clear that we understand how
some substrates, e.g. tau, bind to CaN. Despite having
been first discovered over 40 years ago, there is still
much to learn about CaN [108–110].
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